Brown-Sequard C. E. The effects produced on man by subcutaneous injections of a liquid obtained from the testicules of animals
// Lancet. 1889. July 20. Vol. 2. P. 105–107.Cussons A. J., Bhagat C. I., Fletcher S. J., Walsh J. P. Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment
// The Medical Journal of Australia. 2002. December. Vol. 177. № 11. P. 678–679.Matfin G. The rejuvenation of testosterone: philosopher’s stone or Brown-Séquard Elixir?
// Therapeutic advances in endocrinology and metabolism. 2010. August. Vol. 1. № 4. P. 151–154.Conway A. J., Handelsman D. J., Lording D. W., Stuckey B., Zajac J. D. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing
// The Medical Journal of Australia. 2000. March 6. Vol. 172. № 5. P. 220–224.Clark W. C., Mehl L. Thermal pain: A sensory decision theory analysis of the effect of age and sex on d’ various response criteria, and
50% pain threshold // Journal of Abnormal Psychology. 1971. Vol. 78. № 2. P. 202–212.Lewis S. C., Warlow C. P. How to spot bias and other potential problems in randomised controlled trials
// Journal of Neurology, Neurosurgery & Psychiatry. Vol. 75. № 2. P. 181–187.Hofer A., Hummer M., Huber R., Kurz M., Walch T., Fleischhacker W. W. Selection bias in clinical trials with antipsychotics
// Journal of Clinical Psychopharmacology. 2000. December. Vol. 20. № 6. P. 699–702.Hodges R. D., Scofield A. M. Is spiritual healing a valid and effective therapy?
// Journal of the Royal Society of Medicine. 1995. Vol. 88. № 4. P. 203–207.Abbot N. C., Harkness E. F., Stevinson C., Marshall F. P., Conn D. A., Ernst E. Spiritual healing as a therapy for chronic pain: a randomized, clinical trial
// Pain. 2001. Vol. 91. № 1–2. P. 79–89.Miller L. E., Stewart M. E. The blind leading the blind: Use and misuse of blinding in randomized controlled trials
// Contemporary Clinical Trials. 2011. Vol. 32. № 2. P. 240–243.Misra S. Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies
// Indian journal of sexually transmitted diseases and AIDS. 2012. July-December. Vol. 33. № 2. P. 131–134.Jadad A. R., Enkin M. W. Randomized controlled trials: questions, answers, and musings
. Blackwell Publishing, 2007.George S. L. Perspectives on scientific misconduct and fraud in clinical trials
// Chance. 1997. Vol. 10. № 4. P. 3–5.Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials
// JAMA. 1995. Vol. 273. № 5. P. 408–412.Steneck N. H. Assessing the Integrity of Publicly Funded Research.
A Background Report for the ORI Research Conference on Research Integrity. 2000.George S. L., Buyse M. Data fraud in clinical trials
// Clinical investigation. 2015. Vol. 5. № 2. P. 161–173.Woodhead M. 80% of China’s clinical trial data are fraudulent, investigation finds
// BMJ. 2016. Vol. 355: i5396.Djulbegovic B., Lacevic M., Cantor A., Fields K. K., Bennett C. L., Adams J. R. et al. The uncertainty principle and industry-sponsored research
// Lancet. 2000. August 19. Vol. 356. P. 635–638.Lexchin J., Bero L. A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review
// BMJ. 2003. Vol. 326. P. 1167–1170.